R1 RCM (NASDAQ:RCM) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of R1 RCM (NASDAQ:RCM – Free Report) in a report issued on Thursday morning, Benzinga reports. They currently have a $17.00 price objective on the healthcare provider’s stock. RCM has been the subject of several other reports. Cantor Fitzgerald reiterated an overweight rating and set a […]

Leave a Reply

Your email address will not be published.

Previous post Exxon Mobil’s (XOM) “Sector Perform” Rating Reaffirmed at Royal Bank of Canada
Next post KORU Medical Systems (NASDAQ:KRMD) Stock Rating Reaffirmed by Canaccord Genuity Group